VOR - NASDAQ

Vor Biopharma Inc.

Vor Biopharma Inc.

VORยทNASDAQ

$13.44

-0.037%
HealthcareBiotechnology

Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

StatementsValue Model

At a Glance

Live Snapshot
Market Cap$92.12M
EPS-70.5000
P/E Ratio-0.19
Earnings Date08/11/2026
Vor Biopharma Inc.

Vor Biopharma Inc. Fair Value Envelope

VOR ยท NASDAQ

Our analysis suggests that VOR has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $13.44, this represents a potential HIDDEN relative to our calculated worth for Vor Biopharma Inc..

HIDDEN
Intrinsic Value
Current Price: $13.44

Owner Earnings Valuation Tool

Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation

Historical Financial Data

Base year metrics used for projections

$
%
$
%
$
$

Projection Settings

Forecast period and terminal assumptions

%
%

DCF Valuation Summary

Calculation flow from present value to intrinsic value per share

Present Value-$154.7M
+ Cash & Equivalents$396.5M
Firm Value$241.7M
- Debt$3.0M
Equity Value$238.7M
/ Shares Outstanding6,334,164B
DCF Value$38
UNDERVALUED BY 180%

Owner Earnings Projections

Operating Cash Flow - Maintenance CapEx = Owner Earnings

Metric
Year 1
Year 2
Year 3
Year 4
Year 5
Year 6
Year 7
Year 8
Year 9
Year 10
Operating Cash Flow
-$80.2M
-$45.1M
-$25.3M
-$14.2M
-$8.0M
-$4.5M
-$2.5M
-$1.4M
-$796.4K
-$447.5K
Maintenance CapEx
-$105.7K
-$59.4K
-$33.4K
-$18.8K
-$10.5K
-$5.9K
-$3.3K
-$1.9K
-$1.1K
-$590
Owner Earnings
-$80.3M
-$45.1M
-$25.3M
-$14.2M
-$8.0M
-$4.5M
-$2.5M
-$1.4M
-$797.5K
-$448.1K
Discount Factor
0.926
0.857
0.794
0.735
0.681
0.630
0.583
0.540
0.500
0.463
Present Value
-$74.3M
-$38.7M
-$20.1M
-$10.5M
-$5.4M
-$2.8M
-$1.5M
-$766.8K
-$398.9K
-$207.5K
Terminal Value represents 0.0% of Enterprise Value
Negative Owner Earnings
This company generates negative free cash flow. Consider adjusting maintenance CapEx percentage or check the financial data.

Related Guides

Blog Categories

Continue your VOR research with focused valuation guides.

DCF Modeling

Improve assumptions for intrinsic value accuracy.

Forecasting

Calibrate growth paths and terminal value behavior.

WACC

Refine discount-rate logic for valuation quality.

Cost of Capital

Match risk profile to expected return assumptions.

Research Paths

Pick your next lens
1

Snapshot

Start with context, operating signals, and key market metrics.

2

Value Model

Stress test fair value across bear, base, and bull assumptions.

3

Statements

Validate revenue quality, margins, and balance sheet durability.

4

Earnings Call

Read management commentary and compare it with reported outcomes.

5

Dividends

Check payout sustainability and long-term distribution behavior.

6

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.